A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)

  • By

  • September 15, 2026

  • 1 min

Share

  • 1

    STOPGAP II (EA2234; NCT07001748) is a randomized phase II/III trial in gastric and gastroesophageal junction adenocarcinoma with peritoneal carcinomatosis.

  • 2

    The trial compares intraperitoneal paclitaxel plus systemic treatment with systemic treatment alone.

  • 3

    The study evaluates whether adding paclitaxel directly into the abdominal cavity can reduce the chance of gastric cancer growth or spread.

  • 4

    The trial also evaluates whether intraperitoneal paclitaxel added to intravenous chemotherapy helps patients live longer.

  • 5

    The study aims to determine whether this approach is better or worse than the usual treatment approach for gastric cancer.

Original Source(s)

Related Content